Immunome Inc
Research Immunome Inc (IMNM) on Bullrun: market cap USD 3.33B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMNM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.33B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 53.84M
- Free cash flow-USD 70.65M
Valuation Snapshot
latest market cap is USD 3.33B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.94M | -USD 212.39M | -USD 200.60M | n/a | -2.43 | USD 653.48M | USD 3.86M | USD 634.34M |
| FY2024 | USD 9.04M | -USD 292.96M | -USD 117.97M | n/a | -5 | USD 143.35M | USD 4.83M | USD 181.17M |
| FY2023 | USD 14.02M | -USD 106.81M | -USD 8.40M | n/a | -5.38 | USD 98.68M | USD 1.65M | USD 119.88M |
| FY2022 | n/a | -USD 36.90M | -USD 28.94M | n/a | -3.09 | USD 20.32M | USD 190.00K | USD 16.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.33B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.43B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 684.57M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 457.21M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 26.80M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 156.95M | n/a | n/a | n/a |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immunome Inc's market cap?
Immunome Inc's market capitalization is USD 3.33B.
What does Immunome Inc do?
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.